



PDA Global Headquarters
Bethesda Towers,
Suite 600
4350 East West Highway
Bethesda, MD 20814 USA
TEL: +1 (301) 656-5900
FAX: +1 (301) 986-0296

PDA Europe gGmbH
Am Borsigturm 60
13507 Berlin
Germany

OFFICERS

Chair
Rebecca Devine, PhD
Regulatory Consultant

Chair-Elect
Jette Christensen
Novo Nordisk A/S

Secretary
Steven Lynn
Consultant

Treasurer
Michael Sadowski
Baxter Healthcare

Immediate Past Chair
Martin VanTrieste

President & CEO
Richard M. Johnson

DIRECTORS

Masahiro Akimoto
Otsuka Pharmaceutical
Factory, Inc.

Barbara Allen, PhD
Eli Lilly and Company

Joyce Bloomfield

Véronique Davoust
Pfizer

Ghada Haddad
Merck & Co./Merck
Sharp & Dohme

Mary Oates, PhD

Emma Ramnarine
Roche Pharma

Stephan Rönninger
Amgen

Anil Sawant, PhD
Merck & Co./Merck
Sharp & Dohme

Susan Schniepp
Regulatory Compliance
Associates

Melissa Seymour
Biogen

December 6, 2018

Division of Dockets Management (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Reference: Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up

Docket ID: FDA-1999-D-0081

Dear Sir/Madam:

PDA appreciates FDA's efforts to further clarify its thinking with respect to testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up. PDA commends the inclusion of the *Summary of revisions from the 2006 RCR Guidance* section to aid the audience in comprehension of the revised draft. Additionally, the removal of the need to collect and archive patient samples if RCR testing after 1 year provides negative results is a welcome modification.

The PDA does have one proposed change to submit relating to the draft language regarding the reduction or elimination of RCR testing of ex vivo genetically modified cells based on accumulated manufacturing and clinical data. PDA's recommendation is for the final guidance to provide some indication as to how much data (i.e., number of supernatant lots or ex vivo transduced cells) would need to be provided to support the proposed reduction or elimination of testing.

PDA is a non-profit international professional association of more than 10,000 individual member scientists having an interest in the fields of pharmaceutical, biological, and device manufacturing and quality. Our comments were prepared by a committee of experts with experience in the practice of pharmacy as well as members representing our Biopharmaceutical Advisory Board and Board of Directors.

If there are any questions, please do not hesitate to contact me.

Sincerely,

Richard Johnson
President, PDA

Cc: Tina Morris, PhD, PDA
Josh Eaton, PDA